Kyntra Bio, Inc. (KYNB)
6.11
+0.15
(+2.52%)
USD |
NASDAQ |
Oct 09, 16:00
6.22
+0.11
(+1.80%)
After-Hours: 20:00
Kyntra Bio Cash from Operations (Quarterly) : -3.991M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.991M |
| March 31, 2026 | -13.89M |
| December 31, 2025 | -18.33M |
| September 30, 2025 | -1.847M |
| June 30, 2025 | 12.68M |
| March 31, 2025 | 2.673M |
| December 31, 2024 | -30.47M |
| September 30, 2024 | -8.376M |
| June 30, 2024 | -39.87M |
| March 31, 2024 | -59.29M |
| December 31, 2023 | -18.32M |
| September 30, 2023 | -84.54M |
| June 30, 2023 | -110.57M |
| March 31, 2023 | -101.59M |
| December 31, 2022 | -52.51M |
| September 30, 2022 | -51.88M |
| June 30, 2022 | -33.06M |
| March 31, 2022 | -8.476M |
| December 31, 2021 | -54.96M |
| September 30, 2021 | 44.26M |
| June 30, 2021 | -26.54M |
| March 31, 2021 | -44.98M |
| December 31, 2020 | -7.228M |
| September 30, 2020 | -1.349M |
| June 30, 2020 | 149.66M |
| Date | Value |
|---|---|
| March 31, 2020 | -59.49M |
| December 31, 2019 | -45.05M |
| September 30, 2019 | -27.48M |
| June 30, 2019 | -28.65M |
| March 31, 2019 | 22.48M |
| December 31, 2018 | -17.46M |
| September 30, 2018 | 8.238M |
| June 30, 2018 | -34.98M |
| March 31, 2018 | -31.98M |
| December 31, 2017 | -1.735M |
| September 30, 2017 | -18.51M |
| June 30, 2017 | -19.82M |
| March 31, 2017 | -27.47M |
| December 31, 2016 | -17.86M |
| September 30, 2016 | -1.903M |
| June 30, 2016 | 44.26M |
| March 31, 2016 | -17.39M |
| December 31, 2015 | -39.30M |
| September 30, 2015 | -38.12M |
| June 30, 2015 | 101.05M |
| March 31, 2015 | -42.19M |
| December 31, 2014 | -23.30M |
| September 30, 2014 | -31.53M |
| June 30, 2014 | 92.76M |
| March 31, 2014 | -15.52M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Vericel Corp. | 16.19M |
| Nektar Therapeutics | -75.77M |
| Capricor Therapeutics, Inc. | -31.49M |
| ARS Pharmaceuticals, Inc. | -60.93M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 17.67M |
| Cash from Financing (Quarterly) | -0.005M |
| Free Cash Flow | -38.06M |
| Free Cash Flow Per Share (Quarterly) | -0.9859 |
| Free Cash Flow to Equity (Quarterly) | 15.26M |
| Free Cash Flow to Firm (Quarterly) | -1.623M |
| Free Cash Flow Yield | -154.0% |